Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Atara Biotherapeutics (ATRA)
NASDAQ:ATRA
Atara Biotherapeutics (ATRA) Stock Price & Analysis
1,079 Followers
ATRA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.95 - $63.38
Previous Close$11.01
Volume11.97K
Average Volume (3M)82.11K
Market Cap
$50.51M
Enterprise Value$49.95M
Total Cash (Recent Filing)$46.24M
Total Debt (Recent Filing)$42.20M
Price to Earnings (P/E)―
Beta2.78
Next Earnings
Aug 05, 2024EPS Estimate
-$2.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-36.70
Shares Outstanding4,904,263
10 Day Avg. Volume105,428
30 Day Avg. Volume82,107
Standard Deviation0.26
R-Squared0.01
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)-0.41
Price to Sales (P/S)4.71
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.64
Enterprise Value/Gross Profit5.83
Enterprise Value/Ebitda-0.19
Forecast
1Y Price Target
$26.00Price Target Upside152.43% Upside
Rating ConsensusHold
Number of Analyst Covering5
Atara Biotherapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsATA3219 is designed as an off-the-shelf, allogeneic CD19-directed CAR T-cell therapy, offering easier accessibility compared to autologous treatments.
Financial PerformanceAtara recorded a net loss of $0.23 per share, significantly narrower than the previously estimated net loss of $0.62 per share.
RevenueAtara recorded $27.4M in commercialization and collaboration revenue, surpassing the prior estimate of $3.9M.
Bears Say
Clinical TrialsRisks include failure of tab-cel in EBV+ PTLD patients, rejection of the tab-cel BLA by the FDA, and setbacks with other pipeline candidates.
Financial PerformanceATRA reported 1Q total revenue of $27mn, which was below Goldman Sachs estimate.
Stock DilutionMedium to long-term dilution risk could potentially impact the stock's value.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ATRA FAQ
What was Atara Biotherapeutics’s price range in the past 12 months?
Atara Biotherapeutics lowest stock price was $4.95 and its highest was $63.38 in the past 12 months.
What is Atara Biotherapeutics’s market cap?
Currently, no data Available
When is Atara Biotherapeutics’s upcoming earnings report date?
Atara Biotherapeutics’s upcoming earnings report date is Aug 05, 2024 which is in 14 days.
How were Atara Biotherapeutics’s earnings last quarter?
Atara Biotherapeutics released its earnings results on May 08, 2024. The company reported -$5.75 earnings per share for the quarter, beating the consensus estimate of -$6.417 by $0.667.
Is Atara Biotherapeutics overvalued?
According to Wall Street analysts Atara Biotherapeutics’s price is currently Undervalued.
Does Atara Biotherapeutics pay dividends?
Atara Biotherapeutics does not currently pay dividends.
What is Atara Biotherapeutics’s EPS estimate?
Atara Biotherapeutics’s EPS estimate is -$2.24.
How many shares outstanding does Atara Biotherapeutics have?
Atara Biotherapeutics has 4,904,263 shares outstanding.
What happened to Atara Biotherapeutics’s price movement after its last earnings report?
Atara Biotherapeutics reported an EPS of -$5.75 in its last earnings report, beating expectations of -$6.417. Following the earnings report the stock price went down -3.536%.
Which hedge fund is a major shareholder of Atara Biotherapeutics?
Among the largest hedge funds holding Atara Biotherapeutics’s share is Woodline Partners LP. It holds Atara Biotherapeutics’s shares valued at 1M.
---
Atara Biotherapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$26.00 (152.43% Upside)
$26.00 (152.43% Upside)
Blogger Sentiment
Bullish
ATRA Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 69.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $128.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-79.22%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-45.29%
Trailing 12-Months
Company Description
Atara Biotherapeutics
Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.
---
ATRA Earnings Call
Q3 2023
0:00 / 0:00
---
ATRA Stock 12 Month Forecast
Average Price Target
$26.00
▲(152.43% Upside)
Technical Analysis
Best Analysts Covering ATRA
1 Year
1 Year Success Rate
19/41 ratings generated profit
1 Year Average Return
+12.80%
reiterated a buy rating 6 days ago
Copying John Newman's trades and holding each position for 1 Year would result in 46.34% of your transactions generating a profit, with an average return of +12.80% per trade.
---